Merus N.V.
$90.00+0.00%(+$0.00)
TickerSpark Score
44/100
45
Valuation
20
Profitability
10
Growth
84
Health
60
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRUS research report →
52-Week Range89% of range
Low $33.19
Current $90.00
High $97.14
Companywww.merus.nl
Merus N. V. , a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.
- CEO
- Jan van de Winkel
- IPO
- 2016
- Employees
- 260
- HQ
- Utrecht, NL
Price Chart
+114.03% · this period
Valuation
- Market Cap
- $6.83B
- P/E
- -19.52
- P/S
- 128.91
- P/B
- 10.29
- EV/EBITDA
- -20.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -207.03%
- Op Margin
- -652.96%
- Net Margin
- -658.85%
- ROE
- -50.79%
- ROIC
- -49.38%
Growth & Income
- Revenue
- $34.88M · -12.38%
- Net Income
- $-207,854,187 · -48.10%
- EPS
- $-3.35 · -11.67%
- Op Income
- $-262,626,275
- FCF YoY
- -28.26%
Performance & Tape
- 52W High
- $97.14
- 52W Low
- $33.19
- 50D MA
- $95.61
- 200D MA
- $68.01
- Beta
- 1.06
- Avg Volume
- 1.72M
Get TickerSpark's AI analysis on MRUS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 29, 25 | GENMAB A/S | buy | 1,052,806 |
| Dec 26, 25 | GENMAB A/S | buy | 2,978 |
| Dec 29, 25 | GENMAB A/S | buy | 75,867,199 |
| Dec 26, 25 | GENMAB A/S | buy | 142,610 |
| Dec 24, 25 | GENMAB A/S | buy | 96,082 |
| Dec 23, 25 | GENMAB A/S | buy | 561,042 |
| Dec 22, 25 | GENMAB A/S | buy | 15,710 |
| Dec 19, 25 | GENMAB A/S | buy | 66,264 |
| Dec 18, 25 | GENMAB A/S | buy | 212,177 |
| Dec 17, 25 | GENMAB A/S | buy | 150,795 |
Our MRUS Coverage
We haven't published any research on MRUS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MRUS Report →Similar Companies
CYTK+3.03%
Cytokinetics, Incorporated
$78.77
NUVL+1.31%
Nuvalent, Inc.
$102.32
ABVX+5.43%
Abivax S.A.
$119.90
AXSM+1.74%
Axsome Therapeutics, Inc.
$230.62
MTSR-0.35%
Metsera, Inc.
$70.50
RYTM+3.93%
Rhythm Pharmaceuticals, Inc.
$90.64
JAZZ+0.66%
Jazz Pharmaceuticals plc
$239.01
HALO+0.36%
Halozyme Therapeutics, Inc.
$68.98